Funding for this research was provided by:
Ministry of Education, Culture, Sports, Science and Technology ((B) 16H05329, (B) 24390235)
Article History
Received: 26 July 2018
Accepted: 24 September 2019
First Online: 7 November 2019
Competing interests
: Yasuo Terauchi obtained research support from MSD K.K.; Ono Pharmaceutical Co., Ltd.; Nippon Boehringer Ingelheim Co., Ltd.; Novartis Pharma K.K.; Takeda Pharmaceutical Co., Ltd.; Mitsubishi Tanabe Pharma Corp.; Daiichi Sankyo Co., Ltd.; Sanwa Kagaku Kenkyusho Co., Ltd.; Novo Nordisk Pharma Ltd.; Eli Lilly Japan K.K.; Sanofi K.K.; Dainippon Sumitomo Pharma Co., Ltd.; Shionogi & Co., Ltd.; Bayer Yakuhin, Ltd.; Astellas Pharma, Inc.; Pfizer Japan, Inc.; and AstraZeneca K.K. Yuzuru Ito obtained research support from MSD life science foundation, AstraZeneca K.K., Mitsubishi Tanabe Pharma Corp. and Novartis Pharma K.K. Mitsuyo Kaji and Eri Sakamoto declare that there is no conflict of interest regarding to this work.